Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis.

SETTING National Masan Tuberculosis Hospital, Masan, South Korea. OBJECTIVE To evaluate the pharmacokinetics of prothionamide (PTH) in South Korean patients with multidrug-resistant tuberculosis (MDR-TB) and to investigate whether differences in body mass index (BMI) could explain observed differences in PTH disposition. DESIGN Seventeen patients participated in the study; all had MDR-TB and had received combination anti-tuberculosis treatment, including PTH, cycloserine, ofloxacin, para-aminosalicylic acid and streptomycin or kanamycin, for at least 2 weeks. The patients were divided into two groups based on BMI: Group A (18.5 < or = BMI<23), and Group B (BMI<18.5). Serum samples were collected over 24 h, and the plasma PTH concentration was determined by a validated high-performance liquid chromatography assay. RESULTS After steady-state administration of PTH, the mean area under the plasma concentration-time curve from time 0 to 12 h (AUC(0-12h)) was 11.0 +/- 3.7 microg h/ml. The mean T(max) and t(1/2) were respectively 3.6 h and 2.7 h. No significant difference in PTH disposition was observed between groups A and B, except for ke and t(1/2). CONCLUSION In the pharmacokinetic parameter estimates for PTH in MDR-TB patients during routine treatment, the pharmacokinetics of PTH did not appear to correlate with extent of emaciation in MDR-TB patients.

[1]  G. Bai,et al.  Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. , 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[2]  James C. Sacchettini,et al.  Mechanism of thioamide drug action against tuberculosis and leprosy , 2007, The Journal of experimental medicine.

[3]  R. Abalos,et al.  A clinical trial of ethionamide and prothionamide for treatment of lepromatous leprosy. , 2006, The American journal of tropical medicine and hygiene.

[4]  J. Ollé-Goig,et al.  Outcomes of individualised treatment for multidrug-resistant tuberculosis before DOTS-plus. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[5]  R. Ridzon,et al.  Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients. , 2004, Chest.

[6]  K. Seung,et al.  Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[7]  Charles L Daley,et al.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. , 2003, American journal of respiratory and critical care medicine.

[8]  W. James,et al.  Appropriate Asian body mass indices? , 2002, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[9]  R. Namdar,et al.  Population pharmacokinetics of ethionamide in patients with tuberculosis. , 2002, Tuberculosis.

[10]  H. Rieder Interventions for tuberculosis control and elimination. , 2002 .

[11]  C. Chan,et al.  Serum pharmacokinetics of antimycobacterial drugs in patients with multidrug-resistant tuberculosis during therapy. , 1999, International journal of clinical pharmacology research.

[12]  H. Bartels,et al.  Simple, rapid and sensitive determination of protionamide in human serum by high-performance liquid chromatography. , 1998, Journal of Chromatography B: Biomedical Sciences and Applications.

[13]  C. Peloquin,et al.  Malabsorption of antimycobacterial medications. , 1993, The New England journal of medicine.

[14]  M. Iseman Treatment of multidrug-resistant tuberculosis. , 1993, The New England journal of medicine.

[15]  L. Ackerson,et al.  Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. , 1993, The New England journal of medicine.

[16]  K. Venkatesan Clinical Pharmacokinetic Considerations in the Treatment of Patients with Leprosy , 1989, Clinical pharmacokinetics.

[17]  S. Se,et al.  Plasma levels of ethionamide and prothionamide in a volunteer following intravenous and oral dosages. , 1987 .

[18]  V. Aber,et al.  A comparison of the blood levels and urinary excretion of ethionamide and prothionamide in man. , 1984, The Journal of antimicrobial chemotherapy.

[19]  G. Ellard,et al.  High-performance liquid chromatographic determination of ethionamide and prothionamide in body fluids. , 1981, Journal of chromatography.